Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission

ConclusionsA robust population PK model was built and qualified for entrectinib and M5, describing linear PK for both entities. This model was used to support the ROZLYTREK® new drug application.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research